Internal Server Error

TearSolutions - About the company

TearSolutions is a series B company based in Charlottesville (United States), founded in 2013 by Mark Logan and Gordon Laurie. It operates as a Topical therapeutics for the treatment of dry eye disease. TearSolutions has raised $43M in funding. The company has 59 active competitors, including 17 funded and 12 that have exited. Its top competitors include companies like Lineage Cell Therapeutics, Remegen and Stellular Bio.

Company Details

TearSolutions develop topical therapeutics for the treatment of dry eye disease. Its lead product is a proprietary synthetic fragment of the protein lacritin. The company claims that Lacripep is equipotent with natural lacritin and can alleviate dry-eye symptoms for up to 16 hours. Its currently in phase I clinical trials.
Email ID
*****@tearsolutions.com
Key Metrics
Founded Year
2013
Location
Charlottesville, United States
Stage
Series B
Total Funding
$43M in 11 rounds
Latest Funding Round
Ranked
Employee Count
10 as on Sep 30, 2026
Sign up to download TearSolutions' company profile

TearSolutions's funding and investors

TearSolutions has raised a total funding of $43M over 11 rounds. Its first funding round was on Jun 25, 2014. TearSolutions has 7 institutional investors.

Here is the list of recent funding rounds of TearSolutions:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Oct 29, 2025
6951288
Series B
4802586
6282393
9568298
7236964
Sep 25, 2024
1992196
Series B
5571340
9062059
8909836
2097307
Sep 08, 2023
7401201
Series B
5311524
6996704
6377233
9313345
lockAccess funding benchmarks and valuations. Sign up today!

TearSolutions' founders and board of directors

Founder? Claim Profile
The founders of TearSolutions are Mark Logan and Gordon Laurie.
Here are the details of TearSolutions' key team members:

TearSolutions' employee count trend

TearSolutions has 10 employees as of Sep 26. Here is TearSolutions's employee count trend over the years:
Employee count trend for TearSolutions
lockUncover TearSolutions' growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

TearSolutions's Competitors and alternates

Top competitors of TearSolutions include Lineage Cell Therapeutics, Remegen and Stellular Bio. Here is the list of Top 10 competitors of TearSolutions, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders
$23M
65/100
2nd
Logo for Remegen
Remegen
2008, Yantai (China), Public
Developer of therapies for the treatment of cancer, autoimmune and eye diseases
$100M
62/100
3rd
Logo for Stellular Bio
Stellular Bio
2014, Watertown (United States), Series A
Developer of a platform for producing allogeneic, stem-cell-derived platelet-like cells
$37.5M
59/100
4th
Logo for Valitor
Valitor
2010, Berkeley (United States), Series B
Developer of therapeutic proteins for multiple disease conditions
$38.2M
56/100
5th
Logo for TearSolutions
TearSolutions
2013, Charlottesville (United States), Series B
Topical therapeutics for the treatment of dry eye disease
$43M
54/100
6th
Logo for Retrotope
Retrotope
2006, Los Altos (United States), Acquired
Developer of therapeutics to treat neurodegenerative and ophthalmological diseases
$69.6M
53/100
7th
Logo for Stuart Therapeutics
Stuart Therapeutics
2017, Stuart (United States), Series A
Developer of therapies for treating ophthalmic, gastrointestinal, inflammatory disorders
$11M
53/100
8th
Logo for Biophytis
Biophytis
2006, Romainville (France), Public
Developer of drugs for neuromuscular and age-related diseases
$2.6M
52/100
9th
Logo for OKYO Pharma
OKYO Pharma
2018, London (United Kingdom), Public
Developer of therapeutics for the treatment of dry eye disease and chronic pain management
-
-
52/100
10th
Logo for Azura Ophthalmics
Azura Ophthalmics
1997, Tel Aviv (Israel), Series C
Developing therapies for meibomian gland dysfunction
$37.2M
50/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on TearSolutions's competitors? Click here to see the top ones

TearSolutions's Investments and acquisitions

TearSolutions has made no investments or acquisitions yet.

Reports related to TearSolutions

Here is the latest report on TearSolutions's sector:

News related to TearSolutions

Media has covered TearSolutions for 1 event in last 1 year.
•
TearSolutions Raises $3M in Series B FundingFinSMEs•Nov 21, 2024•TearSolutions
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about TearSolutions

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford